Newsroom

Newsroom

NeoGenomics Schedules its Fourth Quarter and Fiscal Year 2019 Earnings Release for February 27, 2020

Press Release
Read More

NeoGenomics Announces Leadership Appointments

Press Release
Read More

NeoGenomics Acquires Oncology Division from Human Longevity for $37 Million

Press Release
Read More

Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer

Literature
Read More

Comparison of PD-L1 expression in primary and metastatic lung cancer biopsies

Literature
Read More

PD-1 and LAG-3 synergize to drive tumor-infiltration of T cytotoxic cells in NSCLC tumors

Literature
Read More

Phenotypic Characterization of the Immune Landscape in the Bone Marrow of Patients with Acute Myeloid Leukemia (AML) Using MultiOmyx™ Hyperplexed Immunofluorescence Assay

Literature
Read More

EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas

Press Release
Read More

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients